ClinicalTrials.gg

Program

human acellular vessel extra-cellular matrix

Also written as “Acellular Tissue Engineered Vessel (ATEV)”, “Acellular Tissue Engineered Vessel” and “Acellular Tissue Engineered Vessel (Symvess)”.

Its studies are mostly in Vascular System Injuries · Wounds and Injuries · Kidney Failure, Chronic, led by Humacyte.

Furthest: phase 4, since Aug 7, 20264 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Humacyte43 open or runningphase 4since Aug 7, 2026Dec 21, 2016Jun 2027phase 3 · NCT05908084

Also a collaborator on its studies: IQVIA Biotech.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 21, 2016First study: phase 3 study in Wounds and InjuriesFirst studyNCT03005418 · 72 enrolled · United States, Israel
  2. Apr 28, 2023Phase 3 study in Kidney Failure, ChronicNCT05908084 · 121 enrolled · United States
  3. Aug 3, 2026Phase 3 study in Wounds and InjuriesNCT07762313 · 10 planned
  4. Aug 7, 2026Phase 4 study in Vascular System InjuriesNCT07762794 · 125 planned

Ahead

  1. Jun 2027Primary completion: phase 3 study in Kidney Failure, ChronicNCT05908084
  2. Dec 2028Primary completion: phase 3 study in Wounds and InjuriesNCT07762313
  3. Sep 2030Primary completion: phase 4 study in Vascular System InjuriesNCT07762794

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07762794Vascular System Injuries4Not yet recruitingSep 2030125
NCT07762313Wounds and Injuries3Not yet recruitingDec 202810
NCT05908084Kidney Failure, Chronic · United States3Active, not recruitingJun 2027121
NCT03005418Wounds and Injuries · United States, Israel3CompletedSep 19, 202372

How it is read

Names in the registry

  • “Acellular Tissue Engineered Vessel (ATEV)”, 2 entries
  • “Acellular Tissue Engineered Vessel”, 1 entry
  • “Acellular Tissue Engineered Vessel (Symvess)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.